The OPEN MINDS Executive Blueprint for Crisis ManagementBuilding Organizational Sustainability & Success in a Disrupted Health & Human Service Market
A 32-week program designed to help executive teams navigate the business, organizational, operational, and culture changes of a market in turbulence. The program, based on the seven-component OPEN MINDS executive blueprint, combines a series of 35 live educational web briefings with online technical assistance and a suite of on-demand resources.
On December 6, 2019, the U.S. Food and Drug Administration (FDA) released a public safety notice on exosome products due to multiple reports of serious adverse effects experienced by individuals in Nebraska who were treated with unapproved products marketed as containing exosomes. The public safety notice asserts that there are currently no FDA-approved exosome products and clinics offering such products outside of FDA's review process are taking advantage of consumers and pose significant harm . . .